SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

							١	Nashi	ngton, D.C.	2054	19				C		OVAL	
Section 16. Form 4 or Form 5 obligations may continue. See							AT OF CHANGES IN BENEFICIAL OWNERS d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB Number: 3235-02 Estimated average burden hours per response: 0		
transac contrac the pur securit to satis condition	chase or sale of	pursuant to a written plan for of equity r that is intended ve defense																
1. Name a	nd Address of		2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer							
Prior Stephen David						AN2 Therapeutics, Inc. [ANTX]								(Check all applicable) Director 10% Owner				
-														 Officer below) 	(give title	Other below	(specify	
(Last)		,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 11/04/2024									Chief Strategy Officer				
	C/O AN2 THERAPEUTICS, INC.																	
1800 EL CAMINO REAL, SUITE D					4. If Amendment, Date of Original Filed (Month/Day/Year)								6.1	ndividual or .	loint/Group	Filing (Check A	pplicable	
(Street) MENLO PARK CA 94027					_									Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)															
		Tab	ole I - Noi	n-Deriv	ativ	e Se	curitie	s Ac	quired,	Disp	osed o	f, or Be	neficial	ly Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ear)	2A. Deemed Execution Date if any (Month/Day/Yea		r) 8)	tion Disposed nstr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(D)	Price	(Instr. 3				
Common Stock 11/04					4/202	/2024			Α		10,125 ⁽¹⁾ A		\$ <mark>0</mark>	35,342 ⁽²⁾		D		
		-	Table II -						uired, Di , option		,			Owned				
Security (Instr. 3) Or Exerc Price of Derivativ	Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	d Date,	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisa Expiration Date (Month/Day/Year		able and 7. Title and Ar of Securities		nd Amount ties ng e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y Direct (D or Indirec (I) (Instr.	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares					
Stock							20,250		(3)		/03/2034	Common	20,250	\$0	20,250	D		
Option (right to buy)	\$1.08	11/04/2024			A		20,250				1/03/2034	Stock	20,250		20,230			

nits ("RSUs"). RSUs vest as follows: 1/4th of the RSUs vest an illy over four years from Noven of such date.

2. Includes a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

3. The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date.

/s/ Lucy Day, Attorney-in-Fact 11/05/2024 for Stephen David Prior Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.